Summary

Background Topical photodynamic therapy (PDT) is an established treatment option for low-risk basal cell carcinoma (BCC).
Objectives To compare efficacy, cosmesis and tolerability of PDT for BCC with alternative treatments. Methods MEDLINE, PubMed, Embase and CENTRAL databases were searched from inception until 1 September 2017. Included studies were randomized controlled trials (RCTs) of PDT for nodular (n) and superficial (s) BCC reporting at least one of the following outcomes: clearance at 3 months and sustained at 1 or 5 years; recurrence at ≥ 1 year; cosmesis; adverse events; tolerability. Results From 2331 search results, 15 RCTs (2327 patients; 3509 BCCs) were included. PDT efficacy (5-year sustained clearance) was high but inferior to excisional surgery [nBCC pooled risk ratio (RR) 0Á76; 95% confidence interval (CI) 0Á63-0Á91], and without re-treatment of partially responding lesions, was modestly inferior to imiquimod (sBCC: RR 0Á81; 95% CI 0Á70-0Á95) and similar to fluorouracil (sBCC: RR 0Á88; 95% CI 0Á75-1Á04). Five-year sustained clearance was inferior with conventional vs. fractionated PDT (sBCC: RR 0Á76; 95% CI 0Á68-0Á84). PDT cosmesis was superior to surgery (sBCC: RR 1Á68, 95% CI 1Á32-2Á14; nBCC: RR 1Á82, 95% CI 1Á19-2Á80) and cryosurgery (BCC: RR 3Á73, 95% CI 1Á96-7Á07), and without re-treatment of partially responding lesions was similar to imiquimod (sBCC: RR 1Á01, 95% CI 0Á85-1Á19) and fluorouracil (sBCC: RR 1Á04, 95% CI 0Á88-1Á24). Peak pain was higher but of shorter duration with PDT than topical treatments. Serious adverse reactions were rarer with PDT than imiquimod (sBCC: RR 0Á05, 95% CI 0Á00-0Á84) and fluorouracil (sBCC: RR 0Á11, 95% CI 0Á01-2Á04). Combination PDT regimens demonstrated reduced recurrence and improved cosmesis; however, results from these small studies were often nonsignificant. Conclusions PDT is an effective treatment for low-risk BCC, with excellent cosmesis and safety. Imiquimod has higher efficacy than single-cycle PDT but more adverse effects. Highest efficacy is with excisional surgery. Fractionated and combination PDT options warrant further study.
What's already known about this topic
• Topical photodynamic therapy (PDT) is one of a range of established treatment options for low-risk basal cell carcinoma (BCC).
• BCC clearance is reported to be higher with imiquimod than with single-cycle PDT.
What does this study add?
• This is the largest systematic review and meta-analysis to date of PDT for BCC and incorporates National Institute for Health and Care Excellence-approved GRADE assessment of evidence quality, including 15 RCTs (2327 patients with 3509 BCCs).
• Serious adverse reactions are less common with PDT than with imiquimod.
• Peak pain is higher with PDT than topical therapies but is of shorter duration.
• Fractionated PDT offers superior clearance to conventional PDT.
• Combination PDT treatments show promise but require further study.
Basal cell carcinoma (BCC) is the most common cancer worldwide, with reported incidence increasing. 1 BCCs form a substantial and growing proportion of a dermatologist's workload and are a large burden to Western health services. 2 An effective treatment armamentarium is required, alongside prevention strategies. This systematic review examines randomized controlled trials (RCTs) comparing conventional topical photodynamic therapy (PDT) with alternative treatments, including fractionated PDT and combination regimens. Mortality from BCC is low and BCCs almost never metastasize. However, advanced tumours cause considerable morbidity through local tissue destruction, leading to disfigurement and functional compromise. 3 The risk of morbidity depends on tumour location and subtype. The majority of BCCs are low risk, i.e. less aggressive subtypes, superficial BCC (sBCC) and nodular BCC (nBCC), located in anatomical areas that allow uncomplicated resection without substantially impairing function or cosmesis.
Surgical excision allows unparalleled cure rates, but the cosmetic outcome depends on BCC size and location, reconstruction method and expertise. [4] [5] [6] One of several nonsurgical treatments available for nBCC and sBCC is topical PDT with 5-aminolaevulinic acid (ALA) or methyl aminolaevulinate (MAL). [7] [8] [9] The licensed MAL-PDT protocol uses a cycle of two treatments, 1 week apart, with outcome reviewed at 3 months, where it is usual practice to re-treat partially responding lesions. 10 High clearance rate (although lower for nBCC than sBCC), excellent cosmesis and a low adverse event (AE) rate are reported. 9 The objective of this systematic review and meta-analysis of RCTs was to evaluate PDT as a treatment for BCC. Treatment choice is based not only on efficacy, but also tailored to patients' preferences with respect to cosmesis and AEs. 11, 12 This review aims to provide clinicians with comprehensive, up-to-date evidence regarding these outcomes from a review of all available published RCTs of PDT and comparator topical, surgical and combination treatments for low-risk BCC. A further purpose of this work was to inform the development of the updated British Association of Dermatologists and British Photodermatology Group guidelines for topical PDT (2018).
Materials and methods
This systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, 13 and registered with the PROSPERO international prospective register of systematic reviews (2017: CRD42017055804).
Eligibility criteria
Eligible studies are listed in Table 1 . These are published RCTs evaluating topical PDT in adults with BCC with one or more of the following outcomes: clearance of BCCs at 3 months, sustained clearance at 1 year and 5 years; recurrence rates at 1 year or more; cosmesis; severe pain (leading to break in treatment/use of local analgesia); other AE and treatment tolerability.
Data sources and search strategy
A systematic search of the MEDLINE, PubMed, Embase and CENTRAL databases was conducted from inception until 1 September 2017 (see Table S1 for search terms and strategies; see Supporting Information). Only studies reported in English were included. The National Library of Medicine (www.clini caltrials.gov) and European Clinical Trials Database (www.clini caltrialsregister.eu) were reviewed for additional details of clinical trials. Reference lists of included studies were reviewed for further eligible trials. Titles and abstracts of studies were independently screened by three investigators and disagreements were resolved in consultation with a further investigator. Full-text articles were reviewed against an a priori protocol (PROSPERO number 2017:CRD42017055804) and excluded if ineligible (see Table 2 for inclusion/exclusion criteria and Table S2 for details of excluded studies; see Supporting Information).
Data extraction and quality assessment
Data were independently extracted by two investigators using a standard form to record study details (country and setting, randomization unit, study duration, follow-up duration and funding source); population details (patient characteristics, inclusion criteria, exclusion criteria, stratified or subgroup analyses); intervention details (outcome measure, treatment regimen) and results (numbers of patients randomized, analysed, with missing data and with outcome). Differences were resolved by consensus. The methodological quality of each study was assessed using the Cochrane Risk of Bias Tool (Table S3 ; see Supporting Information) and quality of evidence for each outcome was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria (Table S4; see Supporting Information) . 14 
Data analysis
Extracted outcomes were combined for the meta-analysis, where possible, using Review Manager (RevMan 5Á3Á5) and analysed on an intention-to-treat (ITT) basis, using patient data if available and lesion data otherwise. Inconsistency and heterogeneity between studies was assessed using the I 2 test and the v 2 tests, where P < 0Á05 was considered statistically significant.
Results
Study selection
The 2331 results from the systematic search gave 155 articles for full-text assessment, resulting in 15 eligible RCTs published between 2001 and 2017 involving 2327 patients and 3509 BCCs (Fig. 1 ). Most study populations were white, middle-aged and elderly patients, with all but one trial occurring in North America, Europe or Australia. The follow-up ranged from 3 months to >5 years. Treatment protocols for the included studies are summarized in Table 3 .
Photodynamic therapy versus placebo cream photodynamic therapy
Two RCTs, involving 150 primary nBCC, were reported together. 15 A cycle of two treatments, 1 week apart, was performed; at 3 months, partially responding lesions were retreated with a second cycle. All lesions were excised and examined histologically. MAL-PDT showed superior clearance at 3 months after final treatment than placebo PDT [risk ratio (RR) 2Á75, 95% confidence interval (CI) 1Á84-4Á10; Table 4 ] and better cosmesis (RR 3Á00, 95% CI 1Á80-5Á01; Table 5 ), whereas manageable pain was worse (RR 1Á37; 95% CI 1Á14-1Á66; Table 6 ).
Photodynamic therapy versus cryosurgery
Two RCTs compared PDT and cryosurgery; both involved only a single session of PDT (Table 3) . 16, 17 One compared ALA-PDT in both sBCC and nBCC with cryosurgery (two freezethaw cycles, 25-30 s, thawing period 2-4 min). Recurrence was evaluated by biopsy 12 months after final treatment. 16 The other RCT compared MAL-PDT with cryosurgery (≤ 20 s freeze, repeated 2-3 times; Table 3 ). 17 For sBCC there was no significant difference between MAL-PDT and cryosurgery for initial lesion clearance or sustained clearance at 1 year, or in ALA-PDT recurrence rate at 1 year ( Table 4 ). Our ITT analysis demonstrated a reduced sustained clearance at 5 years with single-session MAL-PDT compared with cryosurgery (RR 0Á72, 95% CI 0Á55-0Á95; Table 4 ). This contrasted with the per-protocol analysis reported of recurrence rates of 20% with cryosurgery and 22% with PDT. This discrepancy is influenced by non treatment-related AEs affecting seven patients treated with PDT but only two with cryosurgery. PDT gave superior investigator-assessed cosmesis than cryosurgery at all assessment time points up to 5 years [RR 2Á54, 95% CI 1Á15-5Á59; P < 0Á0001 ( Fig. 2) ]. Patientassessed excellent cosmesis following PDT was superior to cryosurgery at 3 months (RR 2Á13, 95% CI 1Á15-3Á92) but not at 1 or 2 years (Table 5 ). There was no significant difference in treatment tolerability between PDT and cryosurgery (Table 6 ). 17 For nBCC there was no difference in 1-year recurrence rates between cryosurgery and ALA-PDT. 16 ALA-PDT demonstrated better cosmesis than cryosurgery in sBCC and nBCC at 1 year (RR 3Á73, 95% CI 1Á96-7Á07).
Photodynamic therapy versus surgical excision
Three studies of nBCC compared PDT with surgical excision; two studies used ALA and one used MAL (Table 2) . Meta-analysis showed modestly reduced rates of clearance at 3 months with PDT [RR 0Á94, 95% CI 0Á89-0Á99; P = 0Á03 ( Fig. 3) ] and a slightly greater difference at 1 year [RR 0Á90, 95% CI 0Á84-0Á97; P = 0Á006 (Fig. 4) ]. One study compared MAL-PDT with surgical excision of sBCC; 18 PDT did not show inferior rates of clearance at 3 months but did so at 1 year [RR 0Á91, 95% CI 0Á85-0Á96; P = 0Á001 (Table 4) ]. Two nBCC studies (one MAL, one ALA) included recurrence rate at > 1 year and showed PDT had more recurrences than excision [pooled RR 13Á19, 95% CI 2Á58-67Á37; P = 0Á002 (Fig. 5) ]. Clinical recurrence of sBCC after 1 year following the last treatment was 9Á3% in the PDT arm and zero in the surgical excision arm, although 7% of excisions showed positive histological margins. 18 Those studies reporting cosmetic outcome (investigator assessed) showed an advantage of PDT over surgical excision at 1 year for both sBCC (RR 1Á68, 95% CI 1Á32-2Á14; P < 0Á0001) and nBCC [RR 1Á82, 95% CI 1Á19-2Á80; P = 0Á006 (Table 5) ]. 18, 19 Low-to-manageable pain was greater for MAL-PDT than for excision [RR 1Á81, 95% CI 1Á09-3Á01; P = 0Á02 (Table 6) ]. 19 
Photodynamic therapy versus topical treatments
A single RCT compared MAL-PDT with repeated applications of imiquimod or fluorouracil for sBCC. [20] [21] [22] This large RCT involved 601 patients; however, 310 of 911 eligible patients declined to participate, 44% owing to treatment preference. One cycle (two treatments) of MAL-PDT was used, but partially cleared sBCC at 3 months were not re-treated. There was no significant difference between one cycle of MAL-PDT or fluorouracil in clearance at 3 months, 1 or 5 years. MAL-PDT (one cycle) did not show inferior clearance rates to imiquimod at 3 months but did at 1 year (RR 0Á91, 95% CI 0Á83-0Á99; P = 0Á03) and 5 years [RR 0Á81; 95% CI 0Á70-0Á95; P = 0Á01 (Table 4) ].
Compared with PDT, treatment with fluorouracil or imiquimod resulted in more prolonged pain, which intensified throughout the treatment course. The number of patients reporting severe pain per week during each treatment course, calculated using a cumulative measurement (2 weeks for PDT, 4 weeks for fluorouracil and 6 weeks for imiquimod), indicated no difference in severe pain between imiquimod and MAL-PDT (RR 0Á93, 95% CI 0Á61-1Á41; P = 0Á72), whereas fluorouracil demonstrated fewer episodes of severe pain than PDT (RR 1Á93, 95% CI 1Á13-3Á30; Table 6 ). Suspected unexpected serious adverse reactions (SUSARs) reported with imiquimod included influenza-type symptoms (4%) and local wound infections (1%). SUSAR reported with fluorouracil included erysipelas (2%), local wound infection (1%) and leg ulceration (1%). No SUSARs were reported with PDT [see Table 6 and Table S5 (see Supporting Information) for pain and nonpain AEs respectively]. 20 
Photodynamic therapy versus fractionated photodynamic therapy
Two RCTs compared conventional PDT with fractionated ALA-PDT for sBCC (for protocols see Table 3 ). [23] [24] [25] The first involved 195 patients (573 lesions), with single-illumination ALA-PDT as the conventional arm. 23, 24 Fractionated PDT showed greater sustained clearance, together with greater pain, than with single illumination, with the 1-year clearance being 96% vs. 87% (RR 1Á11, 95% CI 1Á05-1Á17; P < 0Á001) and the 5-year clearance being 80% vs. 60% [RR 1Á33, 95% CI 1Á19-1Á47; P < 0Á001 (Table 4) ]. 23, 24 The second RCT, involving 162 patients with one primary sBCC treated per patient, used the one-cycle MAL-PDT protocol without re-treatment of partially responding lesions at 3 months. Treatment failures were excised and scored cosmetically poor. At the 12-month follow-up, 13 treatment failures occurred with MAL-PDT and six with fractionated ALA-PDT, but this was not a statistically significant difference (Table 4) . Goodto-excellent cosmesis occurred more frequently with fractionated PDT (Table 5 ). There was significantly more pain during the second illumination (Table 6) . 25 Photodynamic therapy versus laser or versus laserenhanced photodynamic therapy
Three RCTs compared conventional MAL-PDT and MAL-PDT with prior ablative laser treatment. [26] [27] [28] The largest (286 patients), a within-patient design, compared treatments in patients with three recurrent nBCCs in three arms: MAL-PDT; erbium-doped yttrium-aluminium-garnet (Er:YAG)-laser ablation; Er:YAG-laser ablation plus MAL-PDT. 26 The withinpatient design precluded meta-analysis with the other RCTs. 27 ,28 A 1-year clearance rate of approximately 75% was seen with no significant differences between the three arms ( Table 4 ). Superior cosmesis of the combined treatment to PDT alone was indicated at 3, 6 and 9 months, whereas the laser alone varied (best at 3 months, equal second at 6 months and worst at 9 months); these results were all statistically significant (see Table 5 and Appendix S1; see Supporting Information). The other, smaller, trials involved facial nBCC treatments with prior ablative fractional laser (AFL) treatment; one used CO 2 -AFL, the other Er:YAG-AFL. 27, 28 The clearance rates at 3 months were CO 2 -AFL-PDT 100% vs. PDT 88% and Er:YAG-AFL-PDT 76% vs. PDT 43% (RR 1Á78, 95% CI 1Á03-3Á08). 27, 28 One-year sustained clearance showed no significant difference in the CO 2 -AFL trial (CO 2 laser-PDT 81% vs. PDT 64%). The CO 2 -AFL-PDT vs. PDT trial showed excellent cosmetic outcome in both arms with a tendency towards superior cosmesis with combined treatment (Table 5 ). The AEs in the two trials were typical of PDT treatment (Table 6) , with mildto-moderate pain during illumination, quickly resolving after illumination, together with a range of self-limiting, transient symptoms.
27,28
Photodynamic therapy and placebo cream versus photodynamic therapy and imiquimod
One RCT compared ALA-PDT and imiquimod with ALA-PDT and placebo cream for recurrent BCC. This was a small study (34 patients) and the clearance results reported did not meet our inclusion criteria. However, greater clearance and fewer recurrences were noted in the PDT plus imiquimod arm. Cosmesis was very good in both groups (Table 5) .
Risk of bias
The overall risk of bias for the individual outcomes of each included study varied from low (n = 13; 24%) to high 1035) (n = 35; 65%) to very high (n = 6; 11%). One half of the outcomes with very high overall risk of bias related to the within-patient study. 26 Regarding performance bias, high risk predominated (n = 39; 72%) owing to blinding being precluded by nature of the treatment; the remainder were low risk (n = 15; 28%). All studies showed low risk of detection and other biases. Low risk predominated for the 54 study outcomes in respect of selection (n = 50; 93%), attrition (n = 51; 94%) and outcome reporting (n = 51; 94%) biases (Table S3; see Supporting Information). For outcomes assessable by the GRADE criteria, the overall quality of evidence per outcome varied from moderate to very low, the latter due mainly to imprecision and risk of bias (Table S4 ; see Supporting Information).
Discussion
Overall, this systematic review found that the clearance and recurrence rates with conventional PDT were largely similar to alternative treatments, except for excision, which showed distinctly improved rates. 18, 19, [29] [30] [31] [32] Modestly reduced efficacy was seen with PDT vs. imiquimod in a study where PDT was limited to only one treatment cycle. Strengths of PDT included its excellent cosmesis and lack of serious AEs. Although pain was of higher peak intensity than with topical treatments, it was typically of short duration and limited to the treatment session.
The results from the meta-analyses and the included RCTs indicate that surgical excision is more effective than PDT in both sustained clearance and reducing recurrence. Results were not always statistically significant, with shorter follow-up times, but there was a consistent tendency favouring surgery in both nBCC and sBCC. The data indicate that PDT and cryosurgery have similar clearance and recurrence rates. While higher clearance of sBCC in comparison with nBCC after PDT is widely reported, 9,10 this was not clear from the RCTs analysed and they were not designed to examine this; the single study involving both histological subtypes reported a statistically nonsignificant higher recurrence rate with superficial lesions at 1 year (38% vs. 13%). 16 One RCT compared MAL-PDT with imiquimod or fluorouracil for sBCC. [20] [21] [22] Lesions partially responding to PDT at 3 months were regarded as treatment failures and surgically excised rather than re-treated. There was no significant difference in clearance rates between one cycle of MAL-PDT and courses of either fluorouracil (at 3 months, 1 or 5 years) or imiquimod (at 3 months), whereas at 1 and 5 years imiquimod showed an advantage over PDT. Interestingly, PDT showed substantially greater sustained clearance than imiquimod in treating lower-extremity lesions in older patients; this was, however, a post-hoc subgroup analysis and requires corroboration. 21 Results from included trials demonstrated that, with respect to good-to-excellent cosmesis, PDT for nBCC was superior to placebo and to cryosurgery. Meta-analysis of the two cryosurgery RCTs showed investigator-assessed excellent outcome favouring PDT. An earlier systematic review concluded cosmetic outcome for PDT was significantly better than for surgery; this was confirmed by the four included RCTs. 33 For sBCC, a single RCT showed MAL-PDT gave equivalent cosmesis to imiquimod or fluorouracil, although incompletely responding lesions were not re-treated with PDT but were excised, which was then defined as a poor aesthetic result for PDT. 16 Cosmetic differences between therapies were smaller in patient assessments and diminished with time. 17, 19, 31 The cosmetic advantages of PDT and other topical treatments over surgery can make these more preferable to patients, particularly for sBCC. Pain is a predictable feature of a PDT session and, although generally tolerable, this sometimes required a break in treatment or use of infiltrative local anaesthetic. Low or manageable pain was significantly worse with MAL-PDT than surgical excision, whereas severe AEs, such as wound dehiscence, were avoided with PDT. Modalities differed in the number of treatment sessions, from a single surgical episode to 56 applications of fluorouracil. 16 Pain intensified with treatment repetition; 16 however, pain was primarily evaluated by peak rather than cumulative values, which underestimated the pain experienced over a course of treatment. With PDT, pain was mostly limited to the irradiation period and, although peak pain was greater, it was of much shorter duration than with either imiquimod or fluorouracil. Calculation of cumulative pain showed that there was no difference between imiquimod and MAL-PDT, whereas fluorouracil was less painful than PDT. 20 Recent PDT studies utilizing low irradiance protocols (≤ 35 mW cm À2 vs. 50-200 mW cm
À2
in this review) show reduced pain with apparent preservation of efficacy. [34] [35] [36] [37] [38] Treatment-related AEs, excluding pain, were widely reported in RCTs. Severe local AEs seldom occurred with PDT and mild-to-moderate AEs predominated. Secondary infection was reported following surgery in 0-5% of patients, following fluorouracil in 2% and following imiquimod in 0Á5%, of patients; in contrast, infection following PDT was reported in just one patient throughout all trials, speculatively attributable to the potent antimicrobial action of topical PDT. 18, 20, 39 Following PDT, effects, including weeping, crusting, erosion and ulceration, were less severe and resolved more rapidly than with cryosurgery, imiquimod or fluorouracil. 16, 17, 20 MAL-PDT had fewer reports of moderate-to-severe local swelling, itching, crusting or erosion than either imiquimod or fluorouracil. [20] [21] [22] The nonpain-related AEs were largely transient and of mild-to-moderate intensity after PDT and cryosurgery, and were less frequent following PDT. 16, 17 Of all the treatments, other than placebo cream, superiority was indicated for PDT with respect to nonpain AEs, particularly compared with imiquimod. In practice, advantages of therapeutic options may vary depending on lesion location, lesion and patient characteristics. 12, 40, 41 Patient preferences did not directly feature as outcomes in reviewed RCTs, but it was noted that differences in cosmesis were often less marked when recorded by patients than clinicians. 17, 19 A study of patient preferences showed cure and cosmesis were first priorities, whereby those with head/neck BCCs showed a willingness to trade risk of recurrence for better cosmetic outcome. 11 A systematic review of the needs and experiences of patients with skin cancer found only three studies of keratinocyte carcinoma; no RCT included here considered the psychosocial effects of BCC or its treatment, and the need for further research in this area is No data meeting extraction criteria PDT, photodynamic therapy; mo, month; MAL, methyl aminolaevulinate; y, year; ALA, 5-aminolaevulinic acid; sBCC, superficial basal cell carcinoma; CI, confidence interval; RR, risk ratio; nBCC, nodular basal cell carcinoma; BCC, basal cell carcinoma; IMQ, imiquimod; FU, 5-fluorouracil; Er:YAG, erbium-doped yttrium-aluminium-garnet; AFL, ablative fractional laser; PDD, photodynamic diagnosis. 3 mo, good-to-excellent, MAL-PDT 72% vs. surgery 32% (RR 2Á26, 95% CI 1Á44-3Á54; P < 0.0001); 1 y, good-to-excellent, MAL-PDT 66% vs. surgery 36% (RR 1Á82, 95% CI 1Á19-2Á80; P = 0Á006); 2 y, goodto-excellent, MAL-PDT 48% vs. surgery 34% (RR 1Á41, 95% CI 0Á86-2Á31; P = 0Á17); 5 y, goodto-excellent, MAL-PDT 54% vs. surgery 40% (RR 1Á34, 95% CI 0Á87-2Á06; P = 0Á19) 3 mo, good-to-excellent, MAL-PDT 78% vs. surgery 79% (RR 0Á99, 95% CI 0Á80-1Á22; P = 0Á93); 1 y, good-to-excellent, MAL-PDT 82% vs. surgery 77% (RR 1Á07, 95% CI 0Á87-1Á31; P = 0Á51); 2 y, goodto-excellent, MAL-PDT 56% vs. surgery 57% (RR 0Á97, 95% CI 0Á69-1Á38; P = 0Á89) evident. 40, 41 Cosmesis and AEs need to be taken into account, as well as clearance, to reflect patient's views. 11, 42, 43 The reviewed RCTs also included recent approaches to enhancing clearance with PDT, i.e. fractionation of light dose, assisted penetration of prodrug by skin pretreatment with AFLs and a combination of PDT with another modality. Fractionated illumination showed higher sustained clearance of BCC than single-illumination PDT, but greater pain was seen with fractionation, particularly during the second illumination.
23-25
The RCTs comparing conventional PDT with PDT plus laser pretreatment showed a tendency towards improved clearance in the combination arm, [26] [27] [28] whereas the RCT of conventional PDT vs. PDT plus imiquimod suggested greater clearance and fewer recurrences in the combined treatment arm. 44 These findings indicate that combination PDT warrants further study. The strengths of this systematic review include assessment of quality of studies using the Cochrane Risk of Bias Tool and GRADE criteria, with presentation of ITT analyses and metaanalyses when possible. The scope included all RCTs comparing topical PDT directly with any other treatment for low-risk BCC; hence, this is the most comprehensive systematic review of PDT for BCC to date. 45, 46 Non-English-language studies were not included. The major limitations reflected those of the reviewed studies, including no systematic reporting of patient concerns. 41, 42 A challenge in evaluating clinical trials of PDT is that protocols have varied, including with regard to prodrug used and incubation time; the light source, dosage and irradiance; and number of treatment sessions or cycles given. This severely restricted the ability to pool trial data. The included RCTs partially answered the need, identified in a Cochrane review 10 years ago, for head-to-head trials of effectiveness of BCC treatments, with long-term follow-up. 33 Future RCTs would benefit from including PDT re-treatment of partially responding lesions, as in usual clinical practice, and from reporting subgroup analyses according to anatomical site, lesion size and patient age, particularly as major differences were shown between PDT and imiquimod in older patients with lower-leg lesions.
In conclusion, this systematic review shows that topical PDT, among a range of treatment options, can be used appropriately for low-risk BCCs. The included RCTs demonstrated PDT is a favourable treatment option for cases of superficial and nodular BCC where patients place a high importance upon cosmesis, avoidance of ongoing AEs or potential for severe treatment-related complications. New approaches to improve upon conventional topical PDT outcomes, namely prior use of AFL, fractionated irradiation in PDT or the combination of PDT with other topical treatments, show promise and warrant further exploration in BCC.
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